GATAD2A (GATA Zinc Finger Domain Containing 2A) is a transcriptional repressor protein and core component of the NuRD (Nucleosome Remodeling Deacetylase) complex. It is implicated in [Parkinson's disease](/diseases/parkinsons-disease) risk through genome-wide association studies (GWAS) and plays critical roles in chromatin remodeling, gene regulation, and neuronal survival. [@lauberth2013]
GATAD2A (GATA Zinc Finger Domain Containing 2A) is a transcriptional repressor protein and core component of the NuRD (Nucleosome Remodeling Deacetylase) complex. It is implicated in [Parkinson's disease](/diseases/parkinsons-disease) risk through genome-wide association studies (GWAS) and plays critical roles in chromatin remodeling, gene regulation, and neuronal survival. [@lauberth2013]
Gene Information
| Attribute | Value | |-----------|-------| | Symbol | GATAD2A | | Full Name | GATA Zinc Finger Domain Containing 2A | | Chromosome | 19p13.2 | | NCBI Gene ID | 54898 | | OMIM | 607336 | | Ensembl ID | ENSG00000176165 | | UniProt | Q9ULJ8 | | Protein Length | 593 amino acids |
Function
GATAD2A plays critical roles in gene regulation through its involvement in the NuRD complex:
NuRD Complex Integration
GATAD2A serves as a scaffold protein that brings together multiple enzymatic activities within the NuRD complex:
CHD4/Mi-2α/β: ATP-dependent chromatin remodelers that slide, evict, or restructure nucleosomes
HDAC1/HDAC2: Histone deacetylases that remove acetyl groups from lysine residues
MTA1/2/3: Metastasis-associated proteins that facilitate transcriptional repression
RBBP4/7: Retinoblastoma-binding proteins that interact with histone deacetylases
Transcriptional Repression Mechanisms
The NuRD complex represses gene transcription through multiple coordinated mechanisms [@millar2014]:
Nucleosome remodeling: CHD4 repositioning makes DNA less accessible to transcription factors
DNA methylation cooperation: Interacts with methyl-CpG-binding proteins (MBD1/2) for coordinated silencing
Histone variant replacement: Can replace canonical histones with repressive variants
GATA Zinc Finger Domain
The GATA-type zinc fingers (Cys-X2-Cys-X16-Cys-X2-Cys motif) mediate:
DNA binding to GATA consensus sequences (WGATAR)
Protein-protein interactions with transcription factors
Recruitment of co-repressor complexes
Disease Associations
Parkinson's Disease
GATAD2A has been identified as a genetic risk factor for [Parkinson's disease](/diseases/parkinsons-disease) through GWAS [@nalls2019]. The mechanism involves multiple pathways:
1. Alpha-Synuclein Regulation
GATAD2A may regulate [alpha-synuclein](/proteins/alpha-synuclein) (SNCA) expression through:
Direct binding to the SNCA promoter
Modulation of chromatin accessibility at the SNCA locus
Interaction with other PD risk genes in transcriptional networks
2. Neuronal Survival Pathways
Regulation of genes critical for [dopaminergic neuron](/entities/dopaminergic-neurons) survival
Control of mitochondrial function genes
Modulation of [autophagy](/mechanisms/autophagy-lysosomal) pathways
3. Neuroinflammation
Transcriptional control of [microglial](/entities/microglia) activation genes
Regulation of [neuroinflammatory](/mechanisms/neuroinflammation) responses in [substantia nigra](/brain-regions/substantia-nigra)
Other Neurological Conditions
Huntington's disease: Altered NuRD complex function in striatal [neurons](/entities/neurons)
Rett syndrome: Related to MeCP2 dysfunction in the NuRD network
Cancer: GATAD2A overexpression in various malignancies
Expression
Tissue Distribution
GATAD2A is widely expressed in human tissues:
Brain: High expression in [cortex](/brain-regions/cerebral-cortex), [hippocampus](/brain-regions/hippocampus), [striatum](/brain-regions/striatum)
Neuronal populations: Expressed in various [neurons](/entities/neurons), including [dopaminergic neurons](/entities/dopaminergic-neurons) in the [substantia nigra](/brain-regions/substantia-nigra)
Peripheral tissues: Heart, lung, liver, kidney
Cell Type Specificity
Neurons (high)
Astrocytes (moderate)
Microglia (moderate)
Oligodendrocytes (low-moderate)
Therapeutic Implications
GATAD2A represents a potential therapeutic target through:
HDAC inhibitor synergy: NuRD complex activity can be modulated by HDAC inhibitors
Transcriptional reprogramming: Targeting GATAD2A could normalize dysregulated gene expression
Epigenetic therapy: Modulating chromatin states in [neurons](/entities/neurons)